Protagonist Therapeutics (PTGX) executive compensation, 2026 proxy

Dinesh V. Patel, Ph.D., President and Chief Executive Officer, was paid $12.9M in 2025, up 36% from $9.5M the year before. The CEO-to-median-employee pay ratio was 30:1, on median employee pay of $428,422.

Filed
April 28, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
3
CEO total pay
$12.9M+36% vs prior year
CEO to median employee
30:1median $428,422
CEO pay in equity
89%$11.5M in awards
Prior say-on-pay support
95%of votes cast
CEO At-Risk Compensation
94%Target total direct compensation
Other NEO Average At-Risk Pay
85%Target total direct compensation
Say-on-Pay Support
95%2025 Annual Meeting
Total Employees
124As of December 31, 2025

How Ph.D. was paid

$12.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Stock awards45%Option awards44%Non-equity incentive5%All other compensation0%

Named executive officers

ExecutiveTotal
Dinesh V. Patel, Ph.D.President and Chief Executive Officer$12,871,506
Asif AliEVP, Chief Financial Officer$3,257,489
Arturo Molina, M.D., M.S., F.A.C.P.Chief Medical Officer$4,095,230

What changed and why

  • $12.9MCEO total compensation increased to $12,871,506 in 2025 from $9,473,819 in 2024.
  • 94%94% of the CEO's target total direct compensation was at-risk pay in 2025.
  • 95%At the 2025 Annual Meeting, approximately 95% of the votes cast supported the say-on-pay proposal.
  • The CEO-to-median-employee pay ratio for fiscal 2025 was determined to be 30:1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.